GlassScriptPhysician profile
Beverly N Baxter
NPI 1356431837
$95,212.54
in general payments reported to CMS, 2019-2025
47 companies · $2,199 in 2025
The $2,199 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60K · 2022: $21K · 2023: $7,127 · 2024: $5,058 · 2025: $2,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,314 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,075 · Travel and Lodging: $1,814 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,313.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,075.00 |
| Travel and Lodging | $1,813.69 |
| Education | $180.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $37,567.44 | 2021-2025 | |
| Janssen Biotech, INC. | $19,514.10 | 2021-2025 | Darzalex, Rybrevant, Talvey |
| Amgen INC. | $15,695.68 | 2021-2024 | Lumakras, Kyprolis, Nplate |
| Glaxosmithkline, LLC. | $7,810.89 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Karyopharm Therapeutics INC. | $6,540.88 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $1,117.39 | 2022-2025 | |
| Incyte Corporation | $701.07 | 2022-2025 | Jakafi, Monjuvi, Jakafi |
| Celgene Corporation | $615.60 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $390.06 | 2022-2025 | Onureg, Opdivo, Reblozyl |
| Astellas Pharma US INC | $388.56 | 2023-2025 | Vyloy, Xospata, Padcev |
| Exelixis INC. | $373.79 | 2022-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $331.49 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $324.32 | 2023-2025 | Libtayo |
| Daiichi Sankyo INC. | $309.74 | 2024-2025 | Enhertu |
| Mirati Therapeutics, INC. | $275.47 | 2023-2024 | Krazati |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $258.62 | 2022-2025 | Fruzaqla, Ninlaro |
| Pharmacyclics LLC, An Abbvie Company | $244.93 | 2022-2023 | Imbruvica |
| Beigene USA, INC. | $242.65 | 2023-2025 | Brukinsa |
| Abbvie INC. | $209.66 | 2024-2025 | |
| Beone Medicines USA, INC. | $182.34 | 2025 | Tevimbra, Brukinsa |
| Eisai INC. | $153.22 | 2024-2025 | |
| Pfizer INC. | $143.23 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.54 | 2025 | |
| Aveo Pharmaceuticals, INC. | $119.86 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.29 | 2024-2025 | Gilotrif |
| Emd Serono, INC. | $111.16 | 2024 | |
| Myriad Genetic Laboratories, INC. | $104.85 | 2022 | |
| Genentech, INC. | $103.43 | 2025 | Itovebi |
| Servier Pharmaceuticals LLC | $102.39 | 2023-2025 | |
| Kite Pharma, INC. | $100.61 | 2025 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $86.69 | 2022-2024 | |
| Adaptive Biotechnologies Corporation | $86.42 | 2022 | |
| Alnylam Pharmaceuticals INC. | $82.47 | 2024-2025 | Givlaari |
| Pharmaessentia USA Corporation | $80.26 | 2024-2025 | Besremi |
| Epizyme, INC. | $77.99 | 2022 | |
| Genentech USA, INC. | $74.90 | 2023-2025 | Tecentriq, Alecensa, Phesgo |
| Sobi, INC | $64.30 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $57.24 | 2024-2025 | Onivyde, Somatuline Depot |
| Lilly USA, LLC | $53.17 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Pharmacosmos Therapeutics INC. | $49.01 | 2023-2024 | Monoferric |
| Viiv Healthcare Company | $33.72 | 2025 | Dovato |
| Alexion Pharmaceuticals, INC. | $29.09 | 2025 | Ultomiris |
| Recordati_rare_diseases_inc. | $19.44 | 2024 | Sylvant |
| Tersera Therapeutics LLC | $15.36 | 2024 | Zoladex |
| Agios Pharmaceuticals, INC. | $14.28 | 2025 | Pyrukynd |
| Stemline Therapeutics INC. | $13.94 | 2024 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.